Trials / Completed
CompletedNCT05633225
Central Sensitization and Physical Activity in Adolescents With HSD/hEDS
Measuring Central Sensitization and Physical Activity in Adolescents With Hypermobility Spectrum Disorder or Hypermobile Ehlers-Danlos Syndrome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Vastra Gotaland Region · Other Government
- Sex
- All
- Age
- 13 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
Hypermobility Spectrum Disorder and hypermobile Ehlers-Danlos Syndrome (HSD/hEDS) is under-recognized and poorly understood and its management is therefore not clear. The goal of this study is to better understand pain and its impact on function in the daily activities of adolescents with Hypermobility Spectrum Disorder and/or hypermobile Ehlers-Danlos Syndrome. This study will explore the presence of the pain sensitivity status after physical exercise as well as movement behaviour in adolescents with HSD/hEDS compared to a healthy control group.
Detailed description
All participants will be asked not to undertake physical exercise at least 48 hours before the measurements, and to refrain from consuming caffeine, alcohol or nicotine. For ethical reasons, the patients are allowed to take non-opioid pain medicine as described in the first step of the World Health Organization analgesic ladder (COX-inhibitors and paracetamol), however the patients will be asked to abstain from these medications during the 24 hours period before the measurements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Submax exercise test on a bicycle ergometer | To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value. If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard). |
Timeline
- Start date
- 2022-11-25
- Primary completion
- 2023-06-30
- Completion
- 2023-10-31
- First posted
- 2022-12-01
- Last updated
- 2023-11-07
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05633225. Inclusion in this directory is not an endorsement.